Physician profile
Onercy Ramirez
NPI 1851864615
$1,187.72
in general payments reported to CMS, 2019-2025
11 companies · $52.36 in 2025
The $52.36 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.98 · 2022: $407 · 2023: $413 · 2024: $242 · 2025: $52.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $487.83 | 2022-2024 | Xarelto, Spravato |
| Cvrx, INC. | $164.99 | 2022-2025 | Barostim Neo System |
| Novo Nordisk INC | $137.52 | 2022-2023 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $93.01 | 2021-2022 | |
| Shockwave Medical, INC | $85.06 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $60.43 | 2022-2023 | |
| Amgen INC. | $60.12 | 2022-2023 | Repatha |
| Merck Sharp & Dohme LLC | $31.65 | 2022 | |
| Medtronic, INC. | $30.86 | 2022-2023 | In.Pact Admiral |
| Daiichi Sankyo INC. | $19.30 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Onercy Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.